PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

Jan 26 Reuters Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis the latest Gilead victory in a market share battle with AbbVie over PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

aetna backs gilead's hepatitis c treatment and gets discount - reuters.com reuters aetna inc the thirdlargest us health insurer said it has negotiated a discount with gilead sciences inc for its hepatitis c treatment and will offer it as the preferred choice to its nearly 20 million commercial customers aetna which posted an

update 1-aetna backs gilead's hepatitis c treatment, gets discount - reuters.com adds details of drug policy share prices by caroline humer jan 16 reuters aetna inc the thirdlargest us health insurer said it has negotiated a discount with gilead sciences inc for its hepatitis c treatment and will offer it as the preferred choice to its

refile-aetna backs gilead's hepatitis c treatment, gets discount - reuters.com refiles to take out errant word in first paragraph by caroline humer jan 16 reuters aetna inc the thirdlargest us health insurer said it has negotiated a discount with gilead sciences inc for its hepatitis c treatment and will offer it as the preferred

aetna backs gilead's hepatitis c treatment, gets discount - in.reuters.com jan 16 reuters aetna inc the thirdlargest us health insurer said it negotiated a discount with gilead sciences inc for its hepatitis c treatment and will offer it as the preferred choice to nearly 11 million commercial customers aetna which posted an

abbvie (nyse:abbv) gets approval for its hcv treatment from the eu - stocks.org it was announced by abbvie nyseabbv on january 16 2014 that the european commission has given its approvals for all the hepatitis drugs of the company the drugs are oral and they include exviera and viekirax the company announced that it has

india's refuses patent to gilead for its drug sovaldi - economictimes.indiatimes.com mumbai india's patent office has refused a patent to us drugmaker gilead for its blockbuster drug sovaldi on the grounds that the molecules and compounds of the drug were "known" elements the decision of the patent office comes at a time when indiaus

abbvie wins quick approval for its hep c treatment in europe - fiercepharma.com abbvie $abbv has won european commission approval for its oral hepatitis c cocktail offering some positive news after some disappointments for the us drugmaker in recent months it also sets the stage for the drugmaker to take its marketing battle with

clot-grabbing devices work better than clot-busting drugs for stroke patients: study - delhidailynews.com a new study has suggested that targeting the blocked artery of a person who is having a stroke to remove the clot with a clotgrabbing device is more likely to produce a good recovery than using just clotbusting drugs for treatment the study was done on 500

two-year-olds prescribed drugs for hyperactivity - parentdish.co.uk children as young as two are being prescribed drugs for attention deficit hyperactivity disorder adhd psychologists have warned experts say overstretched health workers are going 'straight to medication' instead of offering behaviour therapy and

new set of proteins to enable development of drugs for cardiac arrhythmia - thenewsreports.com researchers have stumbled upon a new set of proteins dubbed ion channels which they believe will enable development of new drugs for people suffering from cardiac arrhythmia or irregular heartbeat the research has been published in journal elife

View more